1 |
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy, 2019, 39(1): 10-39.
|
2 |
罗高兴, 詹日兴, 袁志强, 等. 浅谈烧伤感染的分类与诊断命名 [J]. 中华烧伤与创面修复杂志, 2023, 39(4): 301-304.
|
3 |
张梓晨, 陈伟, 郑舒芩, 等. 498例成人特重度烧伤患者的临床资料分析 [J]. 昆明医科大学学报, 2022, 43(10): 90-97.
|
4 |
Oczkowski S, Alshamsi F, Belley-Cote E, et al. Surviving Sepsis Campaign Guidelines 2021: highlights for the practicing clinician [J]. Pol Arch Intern Med, 2022, 132(7-8): 16290.
|
5 |
中国医药教育协会感染疾病专业委员会, 中华医学会呼吸病学分会, 中华医学会重症医学分会, 等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识 [J]. 中华结核和呼吸杂志, 2021, 44(4): 292-310.
|
6 |
Munster AM, Xiao GX, Guo Y, et al. Control of endotoxemia in burn patients by use of polymyxin B [J]. J Burn Care Rehabil, 1989, 10(4): 327-330.
|
7 |
Lyons JM, Davis C, Rieman MT, et al. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children [J]. J Burn Care Res, 2006, 27(6): 813-818.
|
8 |
Kang JS, Lee MH. Overview of therapeutic drug monitoring [J]. Korean J Intern Med, 2009, 24(1): 1-10.
|
9 |
Martin-Loeches I. Therapeutic drug monitoring (TDM) in real-time: a need for the present future [J]. Expert Rev Anti Infect Ther, 2022, 20(10): 1245-1247.
|
10 |
Liu X, Huang C, Bergen PJ, et al. Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society [J]. Zhejiang Univ Sci B, 2023, 24(2): 130-142.
|
11 |
Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy [J]. Ann Intensive Care, 2018, 8(1): 66.
|
12 |
Malbrain MLNG, Langer T, Annane D, et al. Intravenous fluid therapy in the perioperative and critical care setting: executive summary of the International Fluid Academy (IFA) [J]. Ann Intensive Care, 2020, 10(1): 64.
|
13 |
Jamal JA, Economou CJ, Lipman J, et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation [J]. Curr Opin Crit Care, 2012, 18(5): 460-471.
|
14 |
Deng Y, Gu JY, Li X, et al. Does monitoring total and free polymyxin B1 plasma concentrations predict polymyxin B-induced nephrotoxicity? A retrospective study in critically ill patients [J]. Infect Dis Ther, 2022, 11(4): 1591-1608.
|
15 |
Sandri AM, Landersdorfer CB, Jovan J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis [J]. J Antimicrob Chemother, 2013, 68(3): 674-677.
|
16 |
张雨昇, 罗雪梅, 成晓亮, 等. CRRT对重症感染患者多黏菌素B血药浓度, 疗效及安全性的影响 [J]. 中国医院药学杂志, 2021, 41(22): 2342-2347.
|
17 |
孙仁华, 刘景全. 重症患者连续性肾脏替代治疗时抗生素剂量调整 [J]. 现代实用医学, 2016, 28(8): 981-984.
|
18 |
Sader HS, Rhomberg PR, Farrell DJ, et al. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15, 377 clinical strains collected worldwide [J]. Diagn Microbiol Infect Dis, 2015, 83(4): 379-381.
|